Richmond, VA, June 29, 2022 – Phlow™ Corp. announced today it has joined a new coalition of diverse stakeholders to address drug shortages in the United States. The End Drug Shortages Alliance provides a forum for key stakeholders to take strategic aim at one of health care’s more pressing and enduring issues, drug shortages that disrupt patient care.
“Phlow is on a bold mission to ensure a future where every American has access to the essential medicines necessary to sustain life and conquer disease. We look forward to actively collaborating with The End Drug Shortages Alliance as we work together to create domestic supply chain resiliency and reliability for our country’s most vital medicines,” said Chris Rogers, EVP Commercial Initiatives at Phlow.
The End Drug Shortages Alliance was launched in late 2021 to bring together industry stakeholders, including providers, group purchasing organizations, manufacturers, distributors and other industry thought leaders and champions. Efforts will focus on improving access to medications through greater transparency across market participants, leading to improved quality manufacturing of medications and production of additional supply.
“We are grateful to have Phlow join the alliance to end drug shortages,” said Eric Tichy, division chair of pharmacy supply solutions for Mayo Clinic, who serves as the Chair for the Alliance advisory board. “Collaboration among organizations strengthens our ability to improve the quality of life for patients that rely on these medications. Together, we can make a difference.”
Learn more at www.EndDrugShortages.com.
About End Drug Shortages Alliance
The End Drugs Shortages Alliance is a collaboration of select health systems, supply chain, industry and other stakeholders including group purchasing organizations, manufacturers, distributors and other industry thought leaders dedicated to solving the pharmaceutical supply challenges that disrupt access to essential medications in the U.S. We prioritize initiatives focused on transparency, quality, redundancy and production of additional supply to achieve undisrupted access to essential medications for health care providers and patients.